Personalised cancer vaccines

Identification of immunogenic neo-epitopes for the development of personalised pancreatic cancer vaccines

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN58774519

Enrollment

100

Registered

2016-09-22

Start date

2016-08-01

Completion date

Unknown

Last updated

2022-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer Cancer

Interventions

Peripheral blood mononuclear cells (PBMCs) obtained from leukocyte filters from healthy individuals will be HLA typed using commercially available reagents from thermofisher scientific. HLA-A2, HLA-D

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Individuals who fulfill the NHS BT requirements for blood donation, which are: 1. fit and healthy 2. weigh over 7 stone 12 lbs or 50kg 3. are aged between 17 and 66 (or 70 if you have given blood before) 4. are over 70 and have given blood in the last two years

Exclusion criteria

Exclusion criteria: Same as NHS BT criteria, which are: 1. receiving treatment 2. taking medication 3. travelling outside of the UK 4. tattoos 5. pregnancy 6. illness 7. cancer 8. received blood, blood products or organs

Design outcomes

Primary

Measure	Time frame
Immunogenicity of neo-epitope candidates selected from available mutanome data using peripheral blood mononuclear cells (PBMCs) from healthy individuals.	—

Countries

England, United Kingdom

Contacts

Public ContactYaohe Wang

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026